Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 5
Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
Authors MacPherson I, Lindsay C, Reed N
Published 16 March 2009 Volume 2009:5 Pages 261—270
DOI https://doi.org/10.2147/TCRM.S3320
Review by Single anonymous peer review
Peer reviewer comments 3
Iain RJ Macpherson, Colin R Lindsay, Nicholas S Reed
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Abstract: Anemia is a common complication of systemic anti-cancer treatment. In this context epoetin beta, like other erythropoiesis-stimulating agents (ESAs), has demonstrable efficacy in raising Hb concentration and reducing the requirement for red cell transfusion. Consequently ESA therapy has gained increasing prominence in the management of chemotherapy-related anemia. However, recent trial data have suggested a higher rate of thromboembolic events, enhanced tumor progression and reduced survival in some patients with cancer who receive ESA therapy. In response, regulatory authorities have mandated increasingly restrictive label changes. In light of these new developments we consider the current role of epoetin beta in the management of chemotherapy-related anemia.
Keywords: anemia, cancer, erythropoietin, epoetin, chemotherapy
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.